Jolanda Howe - 31 Jan 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
SVP, GLOBAL CONTROLLER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
31 Jan 2026
Net transactions value
-$99,998
Form type
4
Filing time
03 Feb 2026, 21:45:05 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Howe Jolanda SVP, GLOBAL CONTROLLER C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 03 Feb 2026 0001974200

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +1,771 +48% 5,471 31 Jan 2026 Direct F1
transaction MIRM Common Stock Sale $99,998 -968 -18% $103.30 4,503 02 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Restricted Stock Units Options Exercise $0 -1,771 -100% $0.000000 0 31 Jan 2026 Common Stock 1,771 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
F2 Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3 The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares vested January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.